
In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.

Your AI-Trained Oncology Knowledge Connection!


Published: June 22nd 2016 | Updated: